Table 5.
Top 5 most statistically significant putative pathways for miRNAs significantly associated with HMO characteristics.
| HMO Summary Measures | Pathway | Merged PFDR |
|---|---|---|
| Diversity | Ubiquitin mediated proteolysis | 1.2x10-47 |
| Pathways in cancer | 8.7x10-47 | |
| Hippo signaling pathway | 1.5x10-43 | |
| Colorectal cancer | 8.7x10-33 | |
| Proteoglycans in cancer | 4.0x10-31 | |
| Sum of HMOs (nmol/mL) | Cell cycle | 2.5x10-104 |
| Pathways in cancer | 3.7x10-102 | |
| p53 signaling pathway | 2.1x10-96 | |
| Proteoglycans in cancer | 4.3x10-92 | |
| FoxO signaling pathway | 1.2x10-84 | |
| HMO-bound sialic acid (nmol/mL) | Focal adhesion | 1.4x10-8 |
| p53 signaling pathway | 1.4x10-8 | |
| Colorectal cancer | 5.3x10-8 | |
| Autophagy-animal | 1.5x10-7 | |
| Small cell lung cancer | 4.5x10-7 | |
| HMO-bound fucose (nmol/mL) | Ubiquitin mediated proteolysis | 1.7x10-63 |
| Pathways in cancer | 3.2x10-63 | |
| p53 signaling pathway | 3.0x10-58 | |
| Proteoglycans in cancer | 3.9x10-49 | |
| Cell cycle | 2.7x10-47 | |
| HMO Concentrations | ||
| 2’FL (nmol/mL) | Ubiquitin mediated proteolysis | 7.5x10-11 |
| Hippo signaling pathway | 5.9x10-8 | |
| Colorectal cancer | 4.2x10-7 | |
| Pathways in cancer | 6.7x10-7 | |
| Oocyte meiosis | 1.4x10-6 | |
| 3’FL (nmol/mL) | Proteoglycans in cancer | 4.4x10-27 |
| Cell cycle | 2.7x10-23 | |
| Pathways in cancer | 5.1x10-23 | |
| Hepatocellular carcinoma | 2.5x10-20 | |
| p53 signaling pathway | 7.0x10-19 | |
| 3’SL (nmol/mL) | Autophagy-animal | 0.04 |
| 6’SL (nmol/mL) | Cell cycle | 9.0x10-10 |
| Chronic myeloid leukemia | 2.1x10-5 | |
| FoxO signaling pathway | 2.1x10-5 | |
| Prostate cancer | 6.5x10-5 | |
| Colorectal cancer | 8.1x10-5 | |
| FLNH (nmol/mL) | Hippo signaling pathway | 2.9x10-6 |
| Salmonella infection | 4.3x10-5 | |
| Cell cycle | 1.4x10-4 | |
| Regulation of actin cytoskeleton | 1.4x10-4 | |
| Focal adhesion | 4.9x10-4 | |
| LNFP I (nmol/mL) | Regulation of actin cytoskeleton | 1.0x10-3 |
| Hippo signaling pathway | 1.4x10-3 | |
| RNA transport | 2.1x10-2 | |
| Proteoglycans in cancer | 4.4x10-2 | |
| MAPK signaling pathway | 4.4x10-2 | |
| LNH (nmol/mL) | Pathways in cancer | 4.9x10-10 |
| Proteoglycans in cancer | 7.7x10-8 | |
| Hippo signaling pathway | 7.9x10-8 | |
| FoxO signaling pathway | 7.9x10-8 | |
| Cell cycle | 2.7x10-7 | |
Putative pathways estimated using miRPath v4.0, KEGG pathway annotation, and TarBase v8.0 targets.